Remove tag patient-numbers
article thumbnail

Haemophilia drug costing $3.5m per dose has been approved

Pharmafile

CSL Behring’s haemophilia B gene therapy has recently been approved by US regulators, however the treatment has an enormous price tag. CSL Behring’s Hemgenix is a one-dose treatment which appeared to reduce the number of bleeding events by 54% over the course of a year. Costing $3.5m read more.

72
article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Last month, Zynteglo (betibeglogene autotemcel), or beti-cel, was approved as a one-time potentially curative gene therapy for patients with beta-thalassaemia who require regular blood transfusions. These approvals represent crucial milestones for bluebird bio, the gene therapy field, and patients with rare genetic diseases.

FDA 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

Anti-Counterfeiting Technologies in Healthcare

Roots Analysis

In order to effectively combat the problems related to counterfeit medicines, several companies have come up with innovative technologies to provide the necessary tools to manufacturers, healthcare professionals and patients to authenticate pharmaceutical products. Such technologies have been shown to have highly secured features.

article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. DMTs for MS have a high price tag, particularly in the US. However, they cannot provide a cure and have a very limited impact on halting disease progression.

98
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. The three agreed on a confidential price, and the TLV determined whether the drug was cost effective for the eligible patient population. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Zolgensma meanwhile is now approved in 45 countries, with over 2,500 patients treated globally across clinical trials, managed access programs, and in the commercial setting. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access. Pause in UK access.

119
119